All set for Covishield?

As India gears up for the Covid vaccination drive from January 16, many people have doubts and concerns about the Oxford-AstraZeneca Covid-19 vaccine. TNIE speaks to an expert

Published: 14th January 2021 04:20 AM  |   Last Updated: 14th January 2021 01:31 PM   |  A+A-

Workers unloading the first consignment of Pune-based Serum Institute’s Covishield vaccine at the regional vaccine store in Thiruvananthapuram on Wednesday | B P Deepu 

Express News Service

KOCHI: How was ‘Covishield’, the Oxford-AstraZeneca Covid-19 vaccine prepared?
Scientists picked a common cold virus that infects the chimpanzee and modified it as a carrier for the RNA of the SARS-CoV-2 spike protein into our cells. So, the carrier inside the vaccine is a modified adenovirus from chimpanzees that is incapable of multiplying or replicating like other viruses.

It is an adenovirus based vaccine. They isolated the DNA from adenovirus in chimpanzees to remove the genes responsible for replication of the virus. So when it enters the human body, it will not replicate and hence is safe. It will only help the body to activate the immune system against SARS-CoV-2 virus.

When the vaccine is injected into our muscles, it will bind with the cells. Following this, our body activates the immune system and antibodies are formed against this SARS-CoV-2. These antibodies will remain in our body. Upon an encounter with the real SARS-CoV-2 virus, these antibodies will act against the virus and destroy it forever.

Some say the  Covishield vaccine is 62% efficient while some claim it is 90%. Which one is true?
Around 23,000 candidates participated in this initial vaccine trial conducted in the United Kingdom (UK) and Brazil. From the UK, 8,895 candidates joined while 2,741 were brought in from Brazil. 

As many as 11,364 candidates received either meningococcal vaccine or placebo (normal saline solution). Out of this, 23,000 candidates, 131 candidates got infected by SARS-COV2. (39  from vaccine group and 92 from placebo group).

Vaccines were administered in two doses. After the initial dose, a second dose was given after a month. A group of candidates received half dose of vaccine one month apart and another group received full dose. 
The former showed efficacy of 90% and those who received full dose showed 62 % efficacy. By combining both results the company claims 70% efficacy. The study conducted on 1,600 participants from India showed more or less identical results. 

Introducing meningococcal vaccine in the placebo group created confusion. It should have been normal saline solutions.
Claims of better efficacy while using half dose as compared to full doesn’t have a proper scientific explanation.
No major complications reported in bulk
The manufacturers claim the vaccine starts protecting the body within two weeks after the vaccine is administered.
It is cheaper and easier to produce.
Can be stored in a common refrigerator (2-8 degree Celsius)
The author is president of the Association of MD Physicians and chairman, board of governors of the Indian Association of Clinical Cardiologists (iacc)


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp